Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers October 15, 2018
Pharmacy Choice - Pharmaceutical News - FDA approves Mylan/Biocon Herceptin biosimilar [Arab Times (Kuwait)] - October 15, 2018

Pharmacy News Article

 12/6/17 - FDA approves Mylan/Biocon Herceptin biosimilar [Arab Times (Kuwait)]

The FDA has approved Mylan and Biocons biosimilar of Roches Herceptin (trastuzumab) breast cancer drug after a delay because of manufacturing issues.

The FDA had previously rejected the biosimilar because of issues at Biocons manufacturing site in Bangalore, India.

Biosimilars are set to save healthcare systems across the world billions of dollars, though originator companies are often still doing everything in their power to delay their arrival.

After its inspectors gave the factory a clean bill of health last month, the FDA has acted quickly to approve the cheaper copycat of Roches blockbuster.

Herceptins US patent does not expire until 2019, but Roche, Mylan and Biocon earlier this year agreed a licensing deal to save themselves the expense of a lengthy court battle, covering all markets around the world except Japan, Brazil and Monaco.

Amgen and Allergan have a Herceptin biosimilar under review in the US, with a decision due halfway through next year.

Branded as Ogivri, Mylan and Biocons biosimilar has been approved for indications included in the label of the reference product, including HER2-overexpressing breast cancer and metastatic stomach cancer.

Total worldwide sales of Herceptin approached $7 billion last year, and around $2.5 billion of that was in the US market.

Late to the party in Europe

Biocon and Mylan have also refiled the biosimilar with the European Medicines Agency after withdrawing the application because of the manufacturing problems.

But this means that rival Samsung Bioepis will have an advantage after beating its rivals to the approval finishing line in Europe, where Herceptin has been off-patent for more than three years.

Celltrions Herceptin biosimilar is also nearing the end of its review in Europe after a filing just over a year ago. Allergan and Amgen have also said they plan to file their Herceptin biosimilar in the EU late this year.

EU reviews usually take more than a year from filing to market authorisation, giving Samsung Bioepis a significant head start over Biocon.

According to press reports, Biocon has now set up a new subsidiary that will deal with all of its biosimilars, including monoclonal antibodies, recombinant insulins, and novel biologics.

(c) 2017 Arab Times Kuwait English Daily. All Rights Reserved. Provided by SyndiGate Media Inc. (

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Last Chance
Oct 16: Management of Alcohol Use Disorders
Last Chance
Oct 17: Telepharmacy- Remote Delivery of Pharmacy Services
Oct 18: Obesity Management: Overview of Pharmacotherapy
Oct 22: An Integrative Approach to Managing Arthritis
Oct 23: NSAIDs, Acetaminophen and Adjuvants in Pain Management
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.

Websites »
Copyright © 2018 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement